Sinopep(688076.SH)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
Sinopep
688076.SH
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was founded in 2009 and is headquartered in Hangzhou, China.
2.520 T
688076.SHMarket value -Rank by Market Cap -/-

Financial Score

10/06/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking102/222
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE10.24%B
    • Profit Margin15.74%A
    • Gross Margin61.97%A
  • Growth ScoreC
    • Revenue YoY5.21%C
    • Net Profit YoY-38.08%D
    • Total Assets YoY25.31%A
    • Net Assets YoY10.35%B
  • Cash ScoreC
    • Cash Flow Margin0.00%D
    • OCF YoY5.21%C
  • Operating ScoreD
    • Turnover0.32D
  • Debt ScoreC
    • Gearing Ratio54.09%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ST Sinopep: Agomelatine tablets are expected to be selected for the 11th batch of national centralized drug procurement

    Zhitong·
    SH
    688076
    -1.63%
    Zhitong·
    SH
    688076
    -1.63%

    Sinopep released its performance for the first three quarters, with a net profit attributable to the parent company of 445 million yuan, an increase of 26.92%

    Zhitong·
    SH
    688076
    -1.63%
    Zhitong·
    SH
    688076
    -1.63%

    Sinopep expects a profit increase, with an estimated net profit attributable to shareholders of 130 million to 140 million yuan in the third quarter, an increase of 5.62% to 13.74% year-on-year

    Zhitong·
    SH
    688076
    -1.63%
    Zhitong·
    SH
    688076
    -1.63%

    Sinopep released its half-year performance, with a net profit attributable to the parent company of 310 million yuan, an increase of 36.49%

    Zhitong·
    SH
    688076
    -1.63%
    Zhitong·
    SH
    688076
    -1.63%

    ST Sinopep, Vazyme and others establish a new biopharmaceutical company

    Zhitong·
    SH
    688105
    +0.22%
    SH
    688076
    -1.63%
    Zhitong·
    SH
    688105
    +0.22%
    SH
    688076
    -1.63%
    © 2026 Longbridge｜Disclaimer